Palisade Bio Announces Study Did Not Achieve Primary Efficacy Endpoint Of Reducing Adhesions In LB1148 Treated Patients Compared To Placebo Treated Patients Post Bowel Resection Surgery
Portfolio Pulse from Benzinga Newsdesk
Palisade Bio announced that its study did not achieve the primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery.
August 09, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Palisade Bio's LB1148 treatment study did not meet its primary efficacy endpoint, which could negatively impact investor sentiment.
The failure of a clinical trial to meet its primary endpoint is typically seen as a negative event for a biotech company. This could lead to a decrease in investor confidence and potentially a drop in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100